-
- ACETECH Technology
- MiraChlor Applications
- Products
- Experience
- Frequently Asked Questions
- About Us
- Contact WooCommerce not Found
- Newsletter
MiraChlor-W™ delivers hypochlorous acid (HOCl) — the same molecule your neutrophils release to fight infection — in its purest, single-species form. It cleanses, supports debridement, and disrupts biofilm without harming the tissue you need to heal.
HOCl is endogenous. White blood cells produce it during the first wave of the immune response. MiraChlor-W delivers it pharmaceutical-grade and pH-tuned, so it works with your healing chemistry instead of against it.
HOCl oxidizes proteins in microbial cell walls. Human cells — with thicker membranes and antioxidant defenses — are spared at the working concentration.
Penetrates and physically disrupts the extracellular matrix where bacteria shelter — a key barrier to closure in chronic and infected wounds.
Loosens slough, necrotic debris, and microorganisms from the wound bed during irrigation and dressing changes, preparing tissue for granulation.
At a skin-friendly pH, fibroblasts keep migrating and granulation tissue keeps forming — moisture balance is maintained, odor is reduced.
Many hypochlorous solutions carry a mix of chlorine species left over from manufacturing — hypochlorite, free chlorine, chlorate, chloramines. MiraChlor-W is made with LETUS's patented electrolytic process to yield pharmaceutical-grade HOCl, the active species, essentially on its own.
Off-target species add cytotoxic load, drift in pH, and shorten potency — without adding antimicrobial benefit.
No residual sodium hypochlorite, chlorate, or chloramines. Purity is what lets the same molecule be both maximally biocidal and gentle on tissue.
Patented production process. MiraChlor-W's HOCl is produced by the LETUS electrolytic method — saltwater electrolysis buffered with sodium bicarbonate — granted by the USPTO. The patent is the engine behind the purity.
MiraChlor-W's safety profile is backed by a full panel of GLP biocompatibility studies conducted to ISO 10993 and US FDA standards. Across cells, skin, and whole-body endpoints, the findings were favorable.
At working dilutions on L929 fibroblasts, cell viability stayed above the 70% acceptance threshold — no cytotoxic effect.
No mortality, abnormal clinical signs, body-weight changes, or gross pathology following intravenous administration.
Intracutaneous reactivity testing showed no erythema or oedema at injection sites and no adverse clinical signs.
Guinea-pig maximization testing produced no delayed (Type IV) hypersensitivity response to the undiluted solution.
Temperature rise stayed below 0.5 °C after intravenous administration — classified non-pyrogenic.
Reviewed by the FDA General & Plastic Surgery panel and found substantially equivalent for its labeled wound-management indications.
GLP studies conducted by an OECD-GLP / ISO 9001 accredited laboratory to ISO 10993 and US FDA guidelines, 2024. Reports on file with LETUS Corporation.
The same pure HOCl, formulated and labeled for two settings — everyday care at home, and professional wound management in the clinic.
HOCl-based irrigation is developed for battlefield wounds, saving thousands from gangrene and sepsis.
Adopted for eye irrigation and infection control — effective on pathogens, compatible with delicate tissue.
HOCl-based solutions clear for chronic wound and burn management — validated for use on compromised tissue.
Surgical site prep and dermatologic infection — treating microbes without disrupting the skin microbiome.
A century of science, refined to single-species purity through a patented process and cleared by the FDA.
Talk to our team about MiraChlor-W for your practice or facility, or find the OTC bottle for home wound care.